HER2 amplification/overexpression is a marker of poor prognosis in breast cancer. The prognostic impact of HER2 positivity is lower in node-negative compared with node-positive women. The only significant, independent prognostic factors in breast cancer are node status, HER2 status and menopausal ...
Furthermore, to make a comprehensive analysis of different types of breast cancer considering the varied PAM50 subtypes and to enhance the reliability of the found outcomes, one more analysis was performed on the GSE45827 dataset64. To dive into detail, PAM50 is one prominent categorization in w...
Approximately 15–20% of human epidermal growth factor receptor 2 (HER2) is amplified and/or overexpressed in breast cancer [5]. HER2-positive BRCA is highly invasive, with short disease-free survival and poor prognosis. The HER2 gene (also known as HER2/neu, c-erbB-2) is located at 17...
Biomarkers of breast cancer such as hormone receptors (HR) and human epidermal growth factor 2 (HER2) can be altered after neoadjuvant chemotherapy (NAC). However, whether the conversion of these receptors affects the prognosis of patients remains to be determined. We sought to evaluate the progno...
However, identifying an independent marker of prognosis has proved more difficult. The human epidermal growth factor receptor-2 (HER2) is amplified/overexpressed in 25–30% of breast tumours. This event has been shown to be associated with poor prognosis in breast cancer patients. Initial ...
1.Tandon A, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-8. 2.Mitri Z, et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Ad...
Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol, 38, 286-90.Chen X, Cong Y, Pan L, et al. Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Cancer Epidemiol. 2014;38(3): 286-290....
(that is, hormone receptors and HER2 expression) show strong association with prognosis and outcome, there are increasing concerns that these variables are limited in their ability to capture the diversity of clinical behaviors of breast cancer and that they would not be sufficient to tailor the ...
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...